Silvia Panigone

Silvia is CEO and founder of ADYA. With about 25 years’ experience and several Board positions, Silvia combines a profound understanding of corporate finance and private investments with a deep knowledge of drug development and diagnostics & devices R&D processes.

She has been appointed as COO (Chief Operating Officer) at NLS Pharmaceutics (NASDAQ:NLSP) since NLS listing at NASDAQ, where she set up the development team and drove the lead asset through IND approval and a successful Phase II in an high speed and cost containment.

She was former Managing Director at I-Bankers Direct, an equity funding web-platform and Advisor for I-Bankers Securities group, a US investment banking. She formerly served as Investment Director at BSI Healthcapital, a VC firm focused on life sciences and she was responsible for venture investments and for the set-up of clients’ dedicated vehicles in the Merchant division of a Swiss bank (BSI/EGF bank). She had a Board Seat in several US- and EU-based companies bringing a few of them up to an exit.

Senior Director at XoVenture, a global network of entrepreneurs in the Life Sciences and Start-Up Coach for the Swiss government (Innosuisse), Silvia acquired an extensive R&D experience, having served in operational and C-level positions in pharmaceutical companies – preclinical, clinical and business development in NLS (NASDAQ:NLSP), Bracco and Quintiles. She spent her first years as oncology researcher in Academia in Italy and the US.

She possesses a Molecular Biology degree, a Ph.D. in Molecular Oncology and EMBA from SDA Bocconi.

15 years experience; intelligent global product development and regulatory affairs consultancy, Director at Clinical Network Services.

30 years experience pre-clinical pharma tox and CMC expert for drugs, cell therapies , food ingredient and medical devices.

30 years experience; M&A, strategy, global channels; software, big data analytics, cybersecurity, diagnostics for women’s health; co-founder of Nasdaq listed bank.
.

One of the most experienced C-level professional with unique expertise in the development of Orphan Drugs and Rare indications in the US and in EU.

Senior scientific analyst – chemistry, biochemistry and neuroscience. R&D consulting, due diligence, business intelligence, IP, value boosters.

15 years experience M&A, corporate finance, healthcare and medtech, supply chain.

Over 25 years’ experience in new product launches and global commercialization infrastructure, publicly traded and private organizations. Ophthalmology focus.